Details

Autor(en) / Beteiligte

• Martinez, Rafael S
• Salji, Mark J
• Rushworth, Linda
• Ntala, Chara
• Rodriguez Blanco, Giovanny
• Hedley, Ann
• Clark, William
• Peixoto, Paul
• Hervouet, Eric
• Renaude, Elodie
• Kung, Sonia H Y
• Galbraith, Laura C A
• Nixon, Colin
• Lilla, Sergio
• MacKay, Gillian M
• Fazli, Ladan
• Gaughan, Luke
• Sumpton, David
• Gleave, Martin E
• Zanivan, Sara
• Blomme, Arnaud
• Leung, Hing Y

Titel

SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer

Ist Teil von

• Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13), p.3664-3678

Ort / Verlag

United States: American Association for Cancer Research

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Androgen deprivation therapy (ADT) is the standard of care for treatment of nonresectable prostate cancer. Despite high treatment efficiency, most patients ultimately develop lethal castration-resistant prostate cancer (CRPC). In this study, we performed a comparative proteomic analysis of three , androgen receptor (AR)-responsive orthograft models of matched hormone-naïve prostate cancer and CRPC. Differential proteomic analysis revealed that distinct molecular mechanisms, including amino acid (AA) and fatty acid metabolism, are involved in the response to ADT in the different models. Despite this heterogeneity, Schlafen family member 5 (SLFN5) was identified as an AR-regulated protein in CRPC. SLFN5 expression was high in CRPC tumors and correlated with poor patient outcome. depletion strongly impaired tumor growth in castrated conditions. Mechanistically, SLFN5 interacted with ATF4 and regulated the expression of LAT1, an essential AA transporter. Consequently, depletion in CRPC cells decreased intracellular levels of essential AA and impaired mTORC1 signaling in a LAT1-dependent manner. These results confirm that these orthograft models recapitulate the high degree of heterogeneity observed in patients with CRPC and further highlight SLFN5 as a clinically relevant target for CRPC. SIGNIFICANCE: This study identifies SLFN5 as a novel regulator of the LAT1 amino acid transporter and an essential contributor to mTORC1 activity in castration-resistant prostate cancer.